I have studied the Consensus Statement on Immunotherapy for Bladder Cancer with great personal interest and care. The first version of this Consensus had a couple of errors one of which in Figure 3 has been acknowledged and corrected in the latest version (attached). The missing issue is regarding treatment with BCG in the High Risk CIS (Figure 1 Flow Chart). The revised version includes a Box that reads "Repeat TUR where indicated". This is very important in cases where after BCG induction the first cystoscopy shows some tumor residuals. The question is what happens with the application of the BCG SWOG schedule? There would be a delay in maintenance, but is that all? The Consensus Statement doesn't clearly address this; yet, given the importance of BCG maintenance, the matter does not seem to be trivial. I have written to Dr. Ashish Kamat, the contact point cited in the Consensus Statement, to please clarify. There might be many BCG patients that have faced this conundrum and have had to interrupt BCG treatment.
jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0271-0 
